Kornimate/medical-research-clean huggingface dataset:
supplementary motor area is a potential target for speech disturbance in parkinson disease

Conditions: Parkinson Disease

Summary: speech disturbance is common in patients with parkinson disease. pharmacotherapy improves motor symptoms but has inconsistent effects on speech disturbance in pd patients. transcranial magnetic stimulation (tms) is a safe and non-invasive tool used for brain stimulation. repetitive transcranial magnetic stimulation (rtms) has positive effects on motor function of pd. yet, its effect on speech disturbance seems to be inconclusive. previous rtms studies mainly focused on the primary motor cortex for pd speech disturbance. nevertheless, we think supplementary motor area (sma) may be a better target. speech disturbance in pd may be associated with basal ganglia-thalamocortical motor circuits and sma involves in the cortex part. in addition, neuroimaging studies showed that sma were under-activation in pd patients. therefore, we conduct this 3-year study including two experiments. the aim of the study is to determine if rtms over sma can improve the speech function of pd patients and change the functional connectivity of speech pathway in the brain. this will be the first study to investigate the effect of rtms over sma on speech.


Eligibility criteria:
experiment 1 inclusion criteria: * right-handed healthy adult volunteers who understand and agree on the informed consent of the study exclusion criteria: * pregnancy or possibility of pregnancy * history of seizure * family history of epilepsy * metals in any part of the body. experiment 2 inclusion criteria: * pd patients with speech disturbance who understand and agree on the informed consent of the study. the speech item scored 2 or 3 in the unified parkinson's disease rating scale (updrs) part iii. exclusion criteria: * dementia * the history of stroke, brain lesion, other central nervous system diseases * the contraindication of tms which described above * any contraindication of mri

Keywords: speech disturbance transcranial magnetic stimulation
a phase iia proof-of-concept study of nc-503 in patients with type ii diabetes

Conditions: Diabetes Mellitus, Type 2; Metabolic Syndrome X

Summary: the main objectives of the current study are to establish the safety and clinical proof-of-concept of nc-503 in inadequately controlled patients with type 2 diabetes and features of metabolic syndrome treated with either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent.

phase iia multi-center, randomized, double-blind, placebo-controlled and parallel-designed study.

Eligibility criteria:
inclusion criteria: * age and gender eligibility: 30 years and older * diagnosis of type 2 diabetes mellitus * patients treated with a stable therapeutic dose of either metformin, a sulfonylurea agent, or metformin in combination with a sulfonylurea agent for a minimum period of 3 months prior to the screening visit * patients must have hba1c level between 7.0-10.0 %, inclusively at screening * the participant must have central obesity (waist circumference) defined per country/ethnic group: europids: men ≥ 94 cm, women ≥ 80 cm; south asian, chinese \& japanese: men ≥ 90 cm, women ≥ 80 cm; and any one of the following metabolic syndrome characteristics at screening: * reduced hdl cholesterol ≤ 1.0 mmol/l * hypertriglyceridemia ≥ 1.7 mmol/l or treatment for dyslipidemia * hypertension: ≥ 130/85 mm hg blood pressure or treatment with antihypertensive medication. * patients must have a glomerular filtration rate (gfr) of ≥ 60 ml/min, and no history of dialysis. exclusion criteria: * patients having received insulin, thiazolidinediones (tzds) or non-thiazolidinedione hypoglycemic agents other than metformin or sulfonylurea agents within three months prior to screening * has had, within the last 6 months, evidence of significant heart disease or stroke, including myocardial infarction, unstable angina, coronary bypass and/or percutaneous transluminal coronary angioplasty (ptca), congestive heart failure (new york heart association class iii-iv), or severe ischemic disease * patients who have an increased red blood cell (rbc) turn-over or thalassemia or anemia * known hiv or history of viral hepatitis type b or c. * any type of diabetes other than type 2 diabetes * significant hepatic enzyme elevation * body mass index (bmi) of \> 40kg/m2 * current or previous use of oral or injectable corticosteroids, or conditions that require the use of corticosteroids, during the three months prior to screening

Keywords: type ii diabetes metabolic syndrome
a trial of shr-1316 maintenance therapy for limited stage small cell lung cancer

Conditions: Limited-stage Small Cell Lung Cancer, LS-SCLC

Summary: shr-1316 as maintenance therapy for limited stage small cell lung cancer without progression after first line platinum based concurrent chemoradiotherapy


Eligibility criteria:
inclusion criteria: 1. the age is 18-75 years old (including both ends), regardless of gender; 2. histologically confirmed limited stage small cell lung cancer ; 3. ecog ps 0 \~ 1; 4. patients received at least 2 cycles of platinum based chemotherapy and radiotherapy, and completed within 1 to 42 days before the first medication. 5. the last chemotherapy must be finished before or at the same time of radiotherapy. 6. the disease did not progress after concurrent chemoradiotherapy; 7. the expected survival time was more than 3 months; 8. pulmonary function: fev1 \> 70%; exclusion criteria: 1. the subjects volunteered to participate in the study, signed the informed consent form, had good compliance and cooperated with the follow-up. 2. mixed sclc or nsclc confirmed by histology; 3. locally advanced small cell lung cancer receiving sequential chemoradiotherapy; 4. have received anti-tumor therapy of systemic immune checkpoint inhibitors for sclc; 5. extensive sclc; 6. operable sclc (clinical stage t1-2n0, except for those who are contraindicated or refuse surgery); 7. interstitial pneumonia 8. history of active, known or suspected autoimmune diseases and autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc. 9. hiv, active hepatitis b or hepatitis c infection
an open-label extension study of ngx-4010 for the treatment of neuropathic pain

Conditions: Herpes Zoster; Neuralgia; Pain; HIV Infections; Peripheral Nervous System Diseases; Diabetic Neuropathies; Diabetes Mellitus; Polyneuropathies

Summary: this study is an open-label, multicenter, extension study for subjects who completed neurogesx study c111 and received treatment with ngx-4010 (capsaicin patch) within 12 weeks (up to +7days) before entry into study c114


Eligibility criteria:
key eligibility criteria: * must have completed neurogesx study c111 and received treatment with ngx-4010 (capsaicin patch) within 12 weeks (up to +7 days) before entry into study c114. * demonstrated adherence to protocol requirements during study c111, and willing and able to comply with protocol requirements for the duration of the study participation. * must not have had any serious adverse experience since enrollment in study c111, whether or not considered to be study drug-related. * must have intact skin at the treatment area. * must be prepared to remain on the same pain medications at the same doses as before the study for the entire duration of the study (36 weeks). * must not use topical pain medications on painful areas. * must be at least 18 years old, not pregnant, and able to take care of self independently, with only occasional assistance if needed. * no history or current problem with substance abuse.

Keywords: dermal assessment pain assessment diary analgesics capsaicin herpes zoster neuralgia pain hiv infections peripheral nervous system diseases diabetic neuropathies diabetes mellitus polyneuropathies complementary therapies
exercise and nutritional rehabilitation in patients with cancer

Conditions: Cachexia; Cancer; Diet Modification; Physical Activity; Advanced Cancer

Summary: in patients with incurable cancer, general deterioration in their ability to walk, exercise and care for themselves is often regarded as an inevitable consequence of this. in 2015, hospice uk published a report advocating "rehabilitative palliative care". however there is limited robust evidence on which to base this approach. reviews of the literature show limited study numbers but do suggest that rehabilitation may be feasible for advanced cancer patients. however key components were not clear and no recommendations could be given. this trial is designed primarily to test the feasibility of a rehabilitation programme (exercise and nutritional supplementation) in advanced cancer patients. feasibility will be the primary outcome measure including rates of recruitment and compliance. secondary outcome measures include impact on physical function, nutritional status, quality of life for patients and their carers. we will also assess the health economic impact by assessing patient health facility use throughout the trial. 40 patients with advanced cancer living in the community will be recruited from two hospice palliative care teams in edinburgh. these patients will be randomised in to either the treatment arm: the rehabilitation programme plus standard care, or the control arm: standard care alone. the treatment arm will consist of an 8 week rehabilitation programme, supervised at weekly clinics by a physiotherapist and dietician. to minimise contamination the control group will be offered the treatment at the end of the 8 weeks (waiting list control). measurements will be made for both groups and compared at baseline (week 0), midpoint (week 5) and endpoint (week 9). recommendations for a larger uk wide trial will be made from the findings of this study.


Eligibility criteria:
inclusion criteria: 1. diagnosis of advanced cancer (defined as metastatic or locally advanced cancer not amenable to curative treatment). 2. outpatient 3. ≥18years 4. karnofsky score ≥ 60 5. prognosis greater than 3 months 6. able to complete trial based assessments 7. under care of community services at marie curie or st columba's hospices 8. ability to comply with trial protocol 9. ability to provide and have capacity to consent 10. agree to attend trial centre for trial related activity (st columba's hospice) exclusion criteria: 1. undergoing anti-cancer therapy (hormonal treatment or bisphosphonates permitted) 2. using enteral nutrition (ng or similar) or parenteral nutrition 3. co-enrolment in drug trials 4. inability to swallow
protein biomarker levels in tissue samples from young patients with low-risk hodgkin lymphoma

Conditions: Lymphoma

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. purpose: this research trial is studying protein biomarker levels in tissue samples from young patients with low-risk hodgkin lymphoma.

objectives: * to investigate the variability of expression of human geminal-center-associated lymphoma (hgal) protein in pediatric low-risk hodgkin lymphoma. * to assess the variability of hgal staining between risk groups by comparing samples from subjects enrolled in the low-risk study ahod0431 with subject samples enrolled in ahod0031 for intermediate-risk classical hodgkin lymphoma (chl). * to assess the variability of hgal staining by evaluating a tissue array created from subjects with intermediate-risk chl. * to correlate rapid or slow early-response in the intermediate-risk group with hgal protein expression. outline: paraffin-embedded tissue samples and tissue microarrays are analyzed for protein expression by ihc.

Eligibility criteria:
disease characteristics: * diagnosed with low-risk classical hodgkin lymphoma (chl) * samples available from patients enrolled in the low-risk study cog-ahod0431 and in the intermediate-risk chl study cog-ahod0031 patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood favorable prognosis hodgkin lymphoma stage i childhood hodgkin lymphoma stage ii childhood hodgkin lymphoma stage iii childhood hodgkin lymphoma stage iv childhood hodgkin lymphoma childhood lymphocyte depletion hodgkin lymphoma childhood lymphocyte predominant hodgkin lymphoma childhood mixed cellularity hodgkin lymphoma childhood nodular lymphocyte predominant hodgkin lymphoma childhood nodular sclerosis hodgkin lymphoma
concomitant, sequential, and standard triple therapy for h. pylori infection

Conditions: Helicobacter Pylori Infection

Summary: to simultaneously compare the efficacies of 7-day triple, 10-day sequential and 7-day quadruple therapies for h. pylori infection in taiwan. consecutive h. pylori-infected patients were randomly assigned to a 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a further 5 days) or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days). the end point is to evaluate the effectiveness of helicobacter pylori eradication rates between three groups.

the purpose of this study is to compare the effectiveness of three h. pylori eradication regimens: 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7 days), 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin and metronidazole for a further 5 days) and 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin and metronidazole for 7 days) in taiwan. a total of 306 subjects are enrolled into this study. h. pylori-infected patients are randomized to a 7-day standard triple therapy, a 10-day sequential therapy, or a 7-day quadruple therapy. eradication efficacy is assessed by a follow-up endoscopy with rapid urease test and histological examination eight weeks after the h. pylori therapy. the eradication rates of three groups will be compared.

Eligibility criteria:
inclusion criteria: * consecutive h. pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis exclusion criteria: * previous h. pylori-eradication therapy * ingestion of antibiotics, bismuth, or proton pump inhibitors within the prior 4 weeks * patients with allergic history to the medications used * patients with previous gastric surgery * the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia) * pregnant women

Keywords: helicobacter pylori infection
kisspeptin administration subcutaneously to patients with reproductive disorders

Conditions: Hypothalamic Amenorrhea; Hypogonadotropic Hypogonadism

Summary: the goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (ha). the investigators are also examining whether kisspeptin can help women release eggs from their ovaries. kisspeptin will be administered subcutaneously (sc) for two weeks in a pulsatile fashion. ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

assignment: all study subjects will undergo the same interventions. delivery of interventions: * the subject will undergo a review of their medical history, physical exam, and screening laboratories. * a pelvic ultrasound will be performed to assess baseline follicular size. * a pump will be placed to administer pulsatile sc kisspeptin for two weeks. * during the course of kisspeptin administration, subjects will * undergo q10 min blood sampling (approximately 4 sessions, 2 hours each) * undergo pelvic ultrasounds (approximately 4 sessions) * optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin

Eligibility criteria:
inclusion criteria: * acquired hypogonadotropic hypogonadism (hypothalamic amenorrhea, aka functional hypothalamic amenorrhea) • confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins\] * normal blood pressure (systolic bp \< 140 mm hg, diastolic \< 90 mm hg) * laboratory studies: * hemoglobin no less than 0.5 g/dl below the lower limit of the reference range for normal women * negative serum hcg pregnancy test at screening (additional urine pregnancy test will be conducted prior to drug administration) * not using hormonal replacement or willing to complete an appropriate washout for that particular medication and method of administration * no current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration exclusion criteria: * any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol * excessive alcohol consumption (\>10 drinks/week) and/or active use of illicit drugs • any active use of marijuana will be evaluated by a study medical professional to determine if it may impact study participation. individuals who regularly use marijuana may be asked to washout as referenced in the medication washout section below * pregnant or trying to become pregnant * breast feeding * history of bilateral oophorectomy (ovaries were removed)

Keywords: hypothalamic amenorrhea hypogonadotropic hypogonadism kisspeptin
a study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in adult patients with generalized myasthenia gravis

Conditions: Generalized Myasthenia Gravis

Summary: the purpose of the mycaringstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (mg).


Eligibility criteria:
inclusion criteria: * participant was eligible for mg0003 \[nct03971422\] or mgc003 at the time of enrollment into either study and the participant either completed the observation period of mg0003 or mgc003 or required rescue therapy during the observation period of the lead-in studies * body weight ≥35 kg at visit 1 * study participants may be male or female exclusion criteria: * evidence of active or latent tuberculosis (tb) as documented by medical history and examination, if applicable, chest x-rays (posterior anterior and lateral), and tb testing by a positive (not indeterminate) quantiferon®-tb gold plus * participant has received a live vaccination within 8 weeks prior to the baseline visit; or intends to have a live vaccination during the course of the study or within 8 weeks following the final dose of study medication * study participant has experienced hypersensitivity reaction after exposure to other anti-neonatal fc receptor (fcrn) drugs - study participant with severe (defined as grade 3 on the myasthenia gravis-activates of daily living (mg-adl) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis * participant has any laboratory abnormality that, in the opinion of the investigator, is clinically significant, has not resolved at randomization, and could jeopardize or compromise the study participant's ability to participate in this study * study participant met any mandatory withdrawal or mandatory study drug discontinuation criteria mg0003 \[nct03971422\] or mgc003, or discontinued study medication in either study, with the exception of discontinuation due to a need for rescue treatment * study participant is not considered capable of adhering to the protocol visit schedule, or medication intake according to the judgment of the investigator * study participant has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or had suicidal ideation since the last visit in mg0003 as indicated by a positive response (yes) to either question 4 or question 5 of the columbia-suicide severity rating scale (c-ssrs)

Keywords: ucb7665 generalized myasthenia gravis rozanolixizumab gmg
hematocrit to hemoglobin ratio and red blood cell distribution width in polycythemia vera and secondary erythrocytosis.

Conditions: Polycythemia Vera

Summary: polycythemia vera (pv), a hematological neoplasm characterized by excessive erythropoiesis due to janus kinase 2 (jak2)- activating mutations. on the other hand, patients with secondary polycythemia (sp), a disorder mostly caused by an increased red cell mass due to chronic hypoxia (i.e, pulmonary disorders and smoking) and erythropoietin-producing tumors (such as leiomyoma, hemangiomas, renal cysts and various carcinomas), are phenotypically slightly different and are usually considered to have significantly better outcomes. red blood cell distribution width (rdw) reflects the heterogeneity of red blood cell sizes (anisocytosis) and is routinely reported as a part of complete blood count by automated instruments in hematology laboratories.

we will collect data about clinical manifestations at the time of diagnosis, history of thrombosis and investigations as complete blood picture, including hematocrit and haemoglobin level, serum uric acid, jak2v617f mutation status by real time pcr (polymerase chain reaction), bone marrow aspiration and biopsy with reticulin stain. patients with secondary erythrocytosis will be included as controls and will be recruited from sohag university hospital especially internal medicine department and chest department.

Eligibility criteria:
inclusion criteria: * all patients aged 18 years and older who were newly diagnosed to have polycythemia vera between september 2014 and november 2022 at sohag university hospital, department of internal medicine, hematology unit and hematology outpatient clinic. exclusion criteria: * patients were excluded if: (1) their disease was not newly diagnosed, (2) their disease met who criteria for chronic, acute myeloid leukemia or other myeloid neoplasms.
evaluation of an internal hospital practice: the effect of altered test tubes sampling order on blood culture contamination rates

Conditions: Septicemia

Summary: implementation of the initial specimen diversion technique, in which the first milliliter of the venipuncture sample is not injected into the culture bottle, led to a significant reduction in blood culture contamination rates. this technique is based on the assumption that the skin plug aspirated during venipuncture is a major source of contaminating bacteria. one such diversion method is aspirating the first blood volume into a blood collection tube. it has, however, been suggested that regular blood collection tubes carry contaminants from the tube's stopper into the blood cultures drawn afterwards, thereby increasing contamination rates. the aim of this trial is to examine the effect of aspirating the first blood volume into a regular blood collection tube on blood culture contamination rate.


Eligibility criteria:
inclusion criteria: * adults evaluated in the emergency room or as inpatients for suspected sepsis or having sepsis and from whom the treating physician plans to take, in the same venous puncture, blood cultures and additional blood tests (blood count and/or blood chemistry). exclusion criteria: * none